In his publication, "Introduction to Pharmacoeconomics", Professor Michael Drummond emphasizes the importance in evaluating a treatment or drug in terms of its impact on health status (i.e., survival, quality of life, specific outcomes) and impact on health care costs (i.e., costs per QALY, hospitalisations, medications, procedures).